Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease, and diseases of the central nervous system. The platform consists of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke), and National Jewish Health (NJH). AEOL 10150 (10150) The company’s major compound, 10150, is being developed under contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services (HHS), as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (‘Pulmonary Acute Radiation Syndrome’ or ‘Lung-ARS’) and the delayed effects of acute radiation exposure. The company is also developing 10150 for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis and other fibrotic diseases. In March 2015, the company announced that 10150 was granted Orphan Drug Designation by the U.S Food and Drug Administration (FDA). The company plans to initiate a Phase 1 safety study in patients with fibrosis in 2016. After the company has completed safety studies, it plans to initiate efficacy studies in patients with fibrosis. The company is also developing 10150 for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control. The company is also developing 10150 as a MCM for exposure to chemical vesicants (chlorine gas, sulfur mustard gas, and phosgene gas) and nerve agents (sarin gas and soman gas) with grant money from the NIH Countermeasures Against Chemical Threats program. 10150 has consistently demonstrated safety and efficacy in animal studies of chemical gas exposure and nerve gas exposure. AEOL 11114B (11114) AEOL 11203 (11203), and AEOL 11207 (11207) The company is developing a second compound, 11114, as a treatment for Parkinson's disease. The company has obtained worldwide, exclusive licenses to develop the compounds from NJH and the UC. The company plans to complete the remaining work to file an Investigational New Drug (IND) application with the FDA by 2017. The company has also evaluated two compounds, 11203 and 11207, for the treatment of Parkinson's disease. AEOL 20415 (20415) In April 2015, the company announced the discovery of a new compound, 20415, which has demonstrated anti-inflammatory and anti-infective properties, and could be effective in treating cystic fibrosis and combatting anti-biotic resistant bacteria. The company has obtained a worldwide, exclusive license to develop the rights to the compound from NJH. The company plans to complete the remaining work to file an IND application with the FDA by 2017. Collaborative and Licensing Arrangements Duke Licenses Pursuant to the company’s license agreements with Duke, the company has obtained exclusive worldwide rights from Duke to products using antioxidant technology and compounds. The license from Duke covers, among other items, AEOL11203, AEOL11207 and some of the intellectual property related to 10150. National Jewish Medical and Research Center (NJMRC) and NJH The company has obtained an exclusive worldwide license from the NJMRC to develop, make, use, and sell products using proprietary information and technology developed under a previous sponsored research agreement within the field of antioxidant compounds and related discoveries. The license from NJMRC covers, among other items, the composition of matter for 10150 and some use patents related to alkylating and vesicant agents. The company has obtained an additional exclusive worldwide license from NJH to develop, make, use, and sell products using proprietary information and technology developed at NJH related to certain compounds as an MCM against mustard gas exposure. In April 2015, the company obtained an exclusive worldwide license from NJH to develop, make, use, and sell products using proprietary information and technology developed at NJH with funding from the company for the treatment of infection caused by bacterial, viral a
aeolus pharmaceuticals inc
26361 Crown Valley Parkway
Mission Viejo, CA 92691
|No competitor information is available for AOLS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact AEOLUS PHARMACEUTICALS INC, please visit www.aeoluspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.